Abstract: The present invention generally relates to novel preparations of mesenchymal stromal cells (MSCs) derived from hemangioblasts, methods for obtaining such MSCs, and methods of treating a pathology using such MSCs. The methods of the present invention produce substantial numbers of MSCs having a potency-retaining youthful phenotype, which are useful in the treatment of pathologies.

Abstract: The present invention generally relates to novel preparations of mesenchymal stromal cells (MSCs) derived from hemangioblasts, methods for obtaining such MSCs, and methods of treating a pathology using such MSCs. The methods of the present invention produce substantial numbers of MSCs having a potency-retaining youthful phenotype, which are useful in the treatment of pathologies.

Abstract: The present invention generally relates to novel preparations of mesenchymal stromal cells (MSCs) derived from hemangioblasts, methods for obtaining such MSCs, and methods of treating a pathology using such MSCs. The methods of the present invention produce substantial numbers of MSCs having a potency-retaining youthful phenotype, which are useful in the treatment of pathologies.

Abstract: The present invention generally relates to novel preparations of mesenchymal stromal cells (MSCs) derived from hemangioblasts, methods for obtaining such MSCs, and method sof treating a pathology using such MSCs. The methods of the present invention produce substantial numbers of MSCs having a potency-retaining youthful phenotype, which are useful in the treatment of pathologies.

Abstract: The present invention generally relates to novel preparations of mesenchymal stromal cells (MSCs) derived from hemangioblasts, methods for obtaining such MSCs, and methods of treating a pathology using such MSCs. The methods of the present invention produce substantial numbers of MSCs having a potency-retaining youthful phenotype, which are useful in the treatment of pathologies.

Abstract: The present invention generally relates to novel preparations of mesenchymal stromal cells (MSCs) derived from hemangioblasts, methods for obtaining such MSCs, and methods of treating a pathology using such MSCs. The methods of the present invention produce substantial numbers of MSCs having a potency-retaining youthful phenotype, which are useful in the treatment of pathologies.

Abstract: The present invention generally relates to novel preparations of mesenchymal stromal cells (MSCs) derived from hemangioblasts, methods for obtaining such MSCs, and methods of treating a pathology using such MSCs. The methods of the present invention produce substantial numbers of MSCs having a potency-retaining youthful phenotype, which are useful in the treatment of pathologies.

Abstract: The present invention generally relates to novel preparations of mesenchymal stromal cells (MSCs) derived from hemangioblasts, methods for obtaining such MSCs, and methods of treating a pathology using such MSCs. The methods of the present invention produce substantial numbers of MSCs having a potency-retaining youthful phenotype, which are useful in the treatment of pathologies.

Abstract: Provided are a fructosylated mangiferin, a preparation method therefor and a use thereof, wherein the fructosylated mangiferin has a structural formula represented by the following formula (I), the method for preparing the fructosylated mangiferin includes adding a substance with fructosylating enzymatic activity to a transformed liquid containing mangiferin for biotransformation reaction, so as to convert the mangiferin into the fructosylated mangiferin, wherein the transformed liquid contains the mangiferin and a glycosyl donor; as well as a use of the fructosylated mangiferin in preparation of a medicament for treatment of tumor-related diseases.

Abstract: Provided are a fructosylated mangiferin, a preparation method therefor and a use thereof, wherein the fructosylated mangiferin has a structural formula represented by the following formula (I), the method for preparing the fructosylated mangiferin includes adding a substance with fructosylating enzymatic activity to a transformed liquid containing mangiferin for biotransformation reaction, so as to convert the mangiferin into the fructosylated mangiferin, wherein the transformed liquid contains the mangiferin and a glycosyl donor; as well as a use of the fructosylated mangiferin in preparation of a medicament for treatment of tumor-related diseases.

Abstract: The present invention generally relates to novel preparations of mesenchymal stromal cells (MSCs) derived from hemangioblasts, methods for obtaining such MSCs, and methods of treating a pathology using such MSCs. The methods of the present invention produce substantial numbers of MSCs having a potency-retaining youthful phenotype, which are useful in the treatment of pathologies.

Abstract: Fructosylated puerarin being converted from puerarin by a bioconversion method conducted in an aqueous phase or nonaqueous phase system, including monofructosyl-(2,6)-puerarin, bifructosyl-(2,6)-puerarin, trifructosyl-(2,6)-puerarin, tetrafructosyl-(2,6)-puerarin and pentafructosyl-(2,6)-puerarin. Tests have shown that the oligosaccharylated puerarin is effective to treat acute myocardial ischemia, and can markedly suppress in vitro the proliferation of human breast cancer cell strain MDA-MB-23 and human chronmyelogenors leukemia cell strain K562, and it has a low toxicity.

Abstract: Fructosylated puerarin being converted from puerarin by a bioconversion method conducted in an aqueous phase or nonaqueous phase system, including monofructosyl-(2,6)-puerarin, bifructosyl-(2,6)-puerarin, trifructosyl-(2,6)-puerarin, tetrafructosyl-(2,6)-puerarin and pentafructosyl-(2,6)-puerarin. Tests have shown that the oligosaccharylated puerarin is effective to treat acute myocardial ischemia, and can markedly suppress in vitro the proliferation of human breast cancer cell strain MDA-MB-23 and human chronmyelogenors leukemia cell strain K562, and it has a low toxicity.

Abstract: Agents for modulating AP-1 mediated gene expression are provided. The modulating agents comprise an internalization moiety and: (1) a peptide sequence isolated from the intracellular domain of Notch-1 (NIC-1); or (2) a peptide analogue or peptidomimetic of the NIC-1 peptide sequence. Methods of using the modulating agents for modulating AP-1 mediated gene expression in a variety of contexts (e.g., for modulating inflammatory and immunosuppressive activities) are provided.